A phase II trial of olaparib monotherapy for patients with germline BRCA1/2-mutated advanced cancer included 23 patients with PDAC and reported a response in 5 patients (21.7%); complete response in 1 (4.3%), and partial response (PR) in 4 (17.4%). This evidence concerns the gene BRCA1 and cancer.